Since reviving a loved one from an opioid overdose Prapela has become my life’s work.
Neonatal Abstinence Syndrome, or NAS, is what babies experience as they withdraw from opioids they were exposed to during pregnancy. The most common symptoms of NAS are respiratory issues followed by low birth weight and difficulty eating.
After hospital discharge, substance-exposed babies continue to be hyperirritable requiring near constant snuggling, rocking and soothing. This constant attention exhausts caregivers and increases the risk for unsafe sleep. While many States and organizations provide baby boxes to reduce the risk of infant sleep mortality what’s needed is a baby box that consoles substance-exposed newborns and helps caregivers get the rest they deserve.
Last week the Prapela® SVS baby box was introduced to do exactly that. SVS is a gentle, random vibration that consoles newborns, is non-habit forming and does not disturb infant sleep cycles. Over twelve years in the making, supported by independent clinical studies, winning several awards including the Next-Gen Baby Box QuickFire Challenge and the Ohio Opioid Technology Challenge has made it possible to offer SVS for home use.
Licensed from Harvard’s Wyss Institute, SVS (Stochastic Vibrotactile Stimulation) is a vibration that stabilizes the brain’s pacemaker neurons supporting cardiorespiratory function. This can stabilize rhythmic breathing and heart rate, which helps babies relax. With independent clinical studies, SVS has proved to help babies relax and breathe across multiple applications.
Next, we are working on the SVS hospital bassinet pad and FDA clearance to treat NAS and help reduce hospital length of stay. Our work in this area is being funded by a grant from the National Institute on Drug Abuse, Pediatric Device Consortium awards funded by the FDA and support from the Charles H. Hood Foundation.
Thank you to every individual and organization for supporting me and Prapela over the past 2 and half years.